Hematologic Malignancies Clinical Trial
Official title:
The Effect of Lavender Oil on Fatigue and Sleep Quality in Patients With Hematologic Malignancy: A Single Blinding Randomized Controlled Study
Verified date | March 2023 |
Source | Istanbul Aydin University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted in a randomized, controlled and experimental manner with patients with hematological malignancies admitted to the Adult Bone Marrow Transplant unit and Hematology-Oncology unit of Acıbadem Altunizade Hospital after obtaining the necessary permissions. The number of patients to be included in the study will be determined by power analysis. The study will include patients who are willing to participate, have no communication problems, are 18 years of age or older, and have no known allergy to lavender oil. Patients with allergies, drug addiction and refusal to participate in the study will not be included in the study. Before the study, patients will be divided into intervention and control groups using a simple random number table. At the beginning of the study, a form including socio-demographic and disease information, Richard Campbell Sleep Quality Scale and Piper Fatigue Scale will be evaluated. Two different options will be used to prevent findings. The first group will be treated with lavender oil and the second group will be treated with saline and 2 drops will be placed on the patient's shoulder 20 minutes before bedtime every night. The application will be started simultaneously with the chemotherapy and will continue until the end of chemotherapy treatment. Sleep and fatigue will be assessed daily using the Richard Campbell Sleep Quality Scale and Piper Fatigue Scale.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | April 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Accepting to participate in the study and being 18 years of age or older - Cooperation, no communication problems - Systolic blood pressure above 100 mmHg (lavender can cause hypotension) - Staying in the bone marrow transplant service for at least two days Exclusion Criteria: - Known diagnosis of a psychiatric illness (anxiety, panic attacks, depression), a known history of allergy and use of anxiolytic drugs. - Having arrhythmia - Do not use sleeping pills - Allergy to any essential oil |
Country | Name | City | State |
---|---|---|---|
Turkey | Dilek Yildirim | Istanbul | Küçükçekmece |
Lead Sponsor | Collaborator |
---|---|
Istanbul Aydin University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Descriptive information form | The form includes demographic data such as age, gender and education level | 1. day. | |
Primary | Richards Campbell Sleep Quality Scale (RCSQ) | The sleep quality of the patients was evaluated three times with the Richards Campbell Sleep Quality Scale: preintervention, postintervention day 1 and postintervention day 2. The Richards Campbell Sleep Quality Scale consists of six items evaluating the depth of the patients' night sleep, the time to fall asleep, the frequency of awakening, the time to stay awake when awakened, the quality of sleep and the noise level in the environment. Each item is evaluated by the patient by questioning the patient's night sleep on a visual analog scale of 0-100. The total score of the scale is obtained from the sum of the five items. The 6th item evaluating the ambient noise level is excluded from the total score evaluation. A score between "0-25" indicates that the quality of the patient's night sleep is very poor and a score between "76-100" indicates that the quality of the patient's night sleep is very good. | 1. day | |
Primary | Richards Campbell Sleep Quality Scale (RCSQ) | The sleep quality of the patients was evaluated three times with the Richards Campbell Sleep Quality Scale: preintervention, postintervention day 1 and postintervention day 2. The Richards Campbell Sleep Quality Scale consists of six items evaluating the depth of the patients' night sleep, the time to fall asleep, the frequency of awakening, the time to stay awake when awakened, the quality of sleep and the noise level in the environment. Each item is evaluated by the patient by questioning the patient's night sleep on a visual analog scale of 0-100. The total score of the scale is obtained from the sum of the five items. The 6th item evaluating the ambient noise level is excluded from the total score evaluation. A score between "0-25" indicates that the quality of the patient's night sleep is very poor and a score between "76-100" indicates that the quality of the patient's night sleep is very good. | 7. day | |
Primary | Piper Fatigue Scale | The scale developed by Piper B. F. et al. in 1998 consists of a total of 22 items and evaluates the patient's subjective perception of fatigue with four sub-dimensions. These are the behavior/severity sub-dimension (6 items; 2-7), which evaluates the impact and severity of fatigue on activities of daily living (ADL); the affect sub-dimension (5 items; 8-12), which covers the emotional meaning attributed to fatigue; the sensory sub-dimension (5 items; 13-17), which reflects the mental, physical and emotional symptoms of fatigue; and the cognitive/mental sub-dimension (6 items; 18-23), which reflects the level of fatigue affecting cognitive functions and mental state. In addition, there are 5 items (1 and 24-27). | 1. day | |
Primary | Piper Fatigue Scale | The scale developed by Piper B. F. et al. in 1998 consists of a total of 22 items and evaluates the patient's subjective perception of fatigue with four sub-dimensions. These are the behavior/severity sub-dimension (6 items; 2-7), which evaluates the impact and severity of fatigue on activities of daily living (ADL); the affect sub-dimension (5 items; 8-12), which covers the emotional meaning attributed to fatigue; the sensory sub-dimension (5 items; 13-17), which reflects the mental, physical and emotional symptoms of fatigue; and the cognitive/mental sub-dimension (6 items; 18-23), which reflects the level of fatigue affecting cognitive functions and mental state. In addition, there are 5 items (1 and 24-27). | 7. day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 |